NCT05937802 is a NA clinical trial of Osmotin in Progressive Multiple Sclerosis, sponsored by Ospedale Policlinico San Martino.

Who is sponsoring NCT05937802?

NCT05937802 is sponsored by Ospedale Policlinico San Martino.

What drugs are being tested in NCT05937802?

Interventions in NCT05937802: Osmotin.

What condition does NCT05937802 study?

NCT05937802 studies Progressive Multiple Sclerosis.

Is NCT05937802 still recruiting?

NCT05937802 is currently status unknown. Last updated 10 July 2023.

Last reviewed 2023-07-10 · How we verify

NCT05937802

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osmotin Plant Protein for Progressive Multiple Sclerosis

Status unknown NA Last updated 10 July 2023

What this trial tests

NA trial testing Osmotin in Progressive Multiple Sclerosis in 50 participants. Status unknown.

Timeline

2 January 2023

Primary endpoint
2 January 2024

2 January 2025

Quick facts

Lead sponsor	Ospedale Policlinico San Martino
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	2 January 2023
Primary completion	2 January 2024
Estimated completion	2 January 2025
Sites	2 locations across Italy

Drugs / interventions tested

Osmotin

Conditions studied

Progressive Multiple Sclerosis — all drugs for Progressive Multiple Sclerosis →

Sponsor

Ospedale Policlinico San Martino

Who can join

Adults 18 to 70, any sex, with Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to explore the anti-inflammatory and neuroprotective effects of a novel nutraceutical product (commercial name Forza™️), consisting of the plant osmotin protein, in patients with progressive multiple sclerosis (PMS). The potential effect on brain metabolism and microstructure will be evaluated by magnetic resonance imaging (MRI) performed six months before starting treatment, at baseline, and after one and six months of treatment. At the same timepoints, electrophysiology, neurofilaments (NfL) quantification, optical coherence tomography (OCT) and clinical assessments will be performed.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetic and Mitochondrial Metabolic Dysfunction in Multiple Sclerosis: A Review of Herbal Drug Approaches and Current Clinical Trials.
Ashwani, Sharma A, Choudhary MK, Gugulothu D, et al · · 2025 · cited 3× · PMID 40180689 · DOI 10.1007/s12035-025-04868-8
Study protocol: Exploratory trial of Forza™, an osmotin-based nutraceutical as adjuvant for the treatment of progressive multiple sclerosis.
Costa V, Aluan K, Schiavetti I, Bason C, et al · · 2025 · PMID 40014609 · DOI 10.1371/journal.pone.0311214

Verify or expand the search:

Other recruiting trials for Progressive Multiple Sclerosis

Currently open trials in the same condition.

NCT07282574 — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrel · Phase 2 · recruiting
NCT07139743 — Obe-cel in Refractory Progressive Forms of Multiple Sclerosis · Phase 1 · recruiting
NCT06675864 — Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 · Phase 1, PHASE2 · recruiting
NCT05811013 — Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis · NA · recruiting
NCT05740722 — Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis · Phase 2 · recruiting

Other Ospedale Policlinico San Martino trials

Trials by the same sponsor.

NCT07029620 — Peripheral Neuropathy Rehabilitation With Stabilometric Platforms (NEUROSTAB) · NA · not yet recruiting
NCT07235111 — Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases · recruiting
NCT06809673 — PA.RI.GE. Study. The Prognostic Role of Inflammatory Circulating Biomarkers in HNSCC: a Prospective Multicentric Trial · enrolling by invitation
NCT06274580 — Endovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild Symptoms · NA · unknown
NCT07061093 — Prospective Evaluation on the Role Exerted by Hormonal Contraceptives on 24-h Blood Pressure. A Prospective Observationa · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05937802 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ospedale Policlinico San Martino
Last refreshed: 10 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05937802.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing